Transfusion medicine
Transfusion transmitted disease
CMV and transfusion

Author: Huy Phu Pham, M.D. (see Authors page)

Revised: 30 October 2017, last major update October 2011

Copyright: (c) 2002-2017, PathologyOutlines.com, Inc.

PubMed Search: CMV and transfusion [title] "loattrfree full text"[sb]

Table of Contents
Definition / general
Cite this page: Pham, H.P. CMV and transfusion . PathologyOutlines.com website. http://pathologyoutlines.com/topic/transfusionmedCMV.html. Accessed November 23rd, 2017.
Definition / general
  • 50 - 85% of U.S. population is CMV+; 50% of U.S. donors are CMV seropositive, compared with 93% in Ghana (Ghana Med J 2006;40:99)
  • Seroconversion rate is 1% per year
  • CMV is almost always latent in immunocompetent adults; CMV virus is latent in leukocytes
  • Leukoreduction reduces risk of CMV transmission
  • Leukoreduced blood products are generally considered equivalent to CMV negative products
  • CMV can cause pneumonitis, hepatitis, retinitis or organ failure in immunocompromised recipients, who should get CMV negative or leukoreduced blood components (Bone Marrow Transplant 2005;36:499, Transfus Med Rev 2005;19:181)